Literature DB >> 25118623

RAS mutations in benign epithelial tumors associated with BRAF inhibitor treatment of melanoma.

Jessica C Hassel1, Leopold Groesser2, Eva Herschberger2, Wilko Weichert3, Christian Hafner2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25118623     DOI： 10.1038/jid.2014.360

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  22 in total

1.  Expression of cell-cycle proteins p53, p21 (WAF-1), PCNA and Ki-67 in benign, premalignant and malignant skin lesions with implicated HPV involvement.

Authors:  S Lu; J Tiekso; S Hietanen; K Syrjänen; V K Havu; S Syrjänen
Journal:  Acta Derm Venereol       Date:  1999-07       Impact factor: 4.437

2.  Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors:  Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2012-06-04       Impact factor: 91.245

3.  Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.

Authors:  Leopold Groesser; Eva Herschberger; Arno Ruetten; Claudia Ruivenkamp; Enrico Lopriore; Markus Zutt; Thomas Langmann; Sebastian Singer; Laura Klingseisen; Wulf Schneider-Brachert; Agusti Toll; Francisco X Real; Michael Landthaler; Christian Hafner
Journal:  Nat Genet       Date:  2012-06-10       Impact factor: 38.330

4.  Squamoproliferative lesions arising in the setting of BRAF inhibition.

Authors:  Nathan T Harvey; Michael Millward; Benjamin A Wood
Journal:  Am J Dermatopathol       Date:  2012-12       Impact factor: 1.533

5.  Different DNA damage and cell cycle checkpoint control in low- and high-risk human papillomavirus infections of the vulva.

Authors:  Lindy A M Santegoets; Romy van Baars; Annelinde Terlou; Claudia Heijmans-Antonissen; Sigrid M A Swagemakers; Peter J van der Spek; Patricia C Ewing; Marc van Beurden; Willem I van der Meijden; Theo J M Helmerhorst; Leen J Blok
Journal:  Int J Cancer       Date:  2011-08-30       Impact factor: 7.396

6.  No human virus sequences detected by next-generation sequencing in benign verrucous skin tumors occurring in BRAF-inhibitor-treated patients.

Authors:  Tina Ganzenmueller; Elias Hage; Yuri Yakushko; Jeanette Kluba; Sabrina Woltemate; Vivien Schacht; Thomas F Schulz; Ralf Gutzmer
Journal:  Exp Dermatol       Date:  2013-11       Impact factor: 3.960

7.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

8.  Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.

Authors:  Emily Y Chu; Karolyn A Wanat; Christopher J Miller; Ravi K Amaravadi; Leslie A Fecher; Marcia S Brose; Suzanne McGettigan; Lydia R Giles; Lynn M Schuchter; John T Seykora; Misha Rosenbach
Journal:  J Am Acad Dermatol       Date:  2012-05-18       Impact factor: 11.527

9.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

10.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Authors:  Fei Su; Amaya Viros; Carla Milagre; Kerstin Trunzer; Gideon Bollag; Olivia Spleiss; Jorge S Reis-Filho; Xiangju Kong; Richard C Koya; Keith T Flaherty; Paul B Chapman; Min Jung Kim; Robert Hayward; Matthew Martin; Hong Yang; Qiongqing Wang; Holly Hilton; Julie S Hang; Johannes Noe; Maryou Lambros; Felipe Geyer; Nathalie Dhomen; Ion Niculescu-Duvaz; Alfonso Zambon; Dan Niculescu-Duvaz; Natasha Preece; Lídia Robert; Nicholas J Otte; Stephen Mok; Damien Kee; Yan Ma; Chao Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Hoa Nguyen; Mark Kockx; Luc Andries; Brian Lestini; Keith B Nolop; Richard J Lee; Andrew K Joe; James L Troy; Rene Gonzalez; Thomas E Hutson; Igor Puzanov; Bartosz Chmielowski; Caroline J Springer; Grant A McArthur; Jeffrey A Sosman; Roger S Lo; Antoni Ribas; Richard Marais
Journal:  N Engl J Med       Date:  2012-01-19       Impact factor: 91.245
View more
  3 in total

1.  Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy.

Authors:  Daniel N Cohen; Steven K Lawson; Aaron C Shaver; Liping Du; Harrison P Nguyen; Qin He; Douglas B Johnson; Wilfred A Lumbang; Brent R Moody; James L Prescott; Pranil K Chandra; Alan S Boyd; Jeffrey P Zwerner; Jason B Robbins; Stephen K Tyring; Peter L Rady; James D Chappell; Yu Shyr; Jeffrey R Infante; Jeffrey A Sosman
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

2.  The Role of Human Papillomaviruses and Polyomaviruses in BRAF-Inhibitor Induced Cutaneous Squamous Cell Carcinoma and Benign Squamoproliferative Lesions.

Authors:  Karin J Purdie; Charlotte M Proby; Hasan Rizvi; Heather Griffin; John Doorbar; Mary Sommerlad; Mariet C Feltkamp; Els Van der Meijden; Gareth J Inman; Andrew P South; Irene M Leigh; Catherine A Harwood
Journal:  Front Microbiol       Date:  2018-08-14       Impact factor: 5.640

Review 3.  Cutaneous Papillomaviruses and Non-melanoma Skin Cancer: Causal Agents or Innocent Bystanders?

Authors:  Daniel Hasche; Sabrina E Vinzón; Frank Rösl
Journal:  Front Microbiol       Date:  2018-05-02       Impact factor: 5.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.